Clinical Trial Update: Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing the combination of everolimus and imatinib for progressive gastrointestinal stromal tumors resistant to imatinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• everolimus + imatinib mesylate

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Progressive Gastrointestinal Stromal Tumor | Phase 4 | Status: COMPLETED